Natalyn Hawk

887 total citations
25 papers, 573 citations indexed

About

Natalyn Hawk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Natalyn Hawk has authored 25 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Natalyn Hawk's work include Cancer Immunotherapy and Biomarkers (7 papers), Esophageal Cancer Research and Treatment (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Natalyn Hawk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Esophageal Cancer Research and Treatment (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Natalyn Hawk collaborates with scholars based in United States, Japan and South Korea. Natalyn Hawk's co-authors include Bassel F. El‐Rayes, John Kauh, Shishir K. Maithel, David A. Kooby, Zhengjia Chen, Edith Brutcher, Jerome C. Landry, Hemchandra Mahaseth, Sungjin Kim and Ruth O’Regan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Natalyn Hawk

25 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Natalyn Hawk United States	9	432	175	164	126	118	25	573
Amy Sheen Australia	15	247 0.6×	250 1.4×	118 0.7×	116 0.9×	69 0.6×	30	627
Emmanuelle Samalin France	16	562 1.3×	353 2.0×	111 0.7×	137 1.1×	114 1.0×	75	827
Ji Eun Uhm South Korea	15	340 0.8×	263 1.5×	96 0.6×	74 0.6×	107 0.9×	24	621
Virginia Cappagli Italy	18	308 0.7×	149 0.9×	216 1.3×	238 1.9×	95 0.8×	38	1.1k
Sehhoon Park South Korea	14	291 0.7×	124 0.7×	157 1.0×	96 0.8×	46 0.4×	53	499
Marta Martín-Richard Spain	17	483 1.1×	238 1.4×	80 0.5×	150 1.2×	148 1.3×	42	708
Silvia Bozzarelli Italy	12	281 0.7×	131 0.7×	95 0.6×	88 0.7×	116 1.0×	54	522
James E. Krook United States	7	297 0.7×	138 0.8×	92 0.6×	70 0.6×	110 0.9×	9	427
Daniel Lee South Korea	12	519 1.2×	631 3.6×	101 0.6×	197 1.6×	100 0.8×	35	850

Countries citing papers authored by Natalyn Hawk

Since Specialization

Citations

This map shows the geographic impact of Natalyn Hawk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalyn Hawk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalyn Hawk more than expected).

Fields of papers citing papers by Natalyn Hawk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalyn Hawk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalyn Hawk. The network helps show where Natalyn Hawk may publish in the future.

Co-authorship network of co-authors of Natalyn Hawk

This figure shows the co-authorship network connecting the top 25 collaborators of Natalyn Hawk. A scholar is included among the top collaborators of Natalyn Hawk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalyn Hawk. Natalyn Hawk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2022). Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 112(5). e43–e44. 2 indexed citations

Tabernero, Josep, Deirdre Jill Cohen, Eric Van Cutsem, et al.. (2021). P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. Annals of Oncology. 32. S151–S152. 4 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, Lillian L. Siu, et al.. (2021). P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology. 118. 10–11. 1 indexed citations

Yoshino, Takayuki, Roxana Fu, Natalyn Hawk, et al.. (2021). 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study. Annals of Oncology. 32. S580–S580. 4 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2020). 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. SHILAP Revista de lepidopterología. A214.1–A214. 2 indexed citations

Zaidi, Mohammad Y., Cecilia G. Ethun, Theresa Gillespie, et al.. (2018). Identifying the barriers to gastric cancer care at safety‐net hospitals: A novel comparison of a safety‐net hospital to a neighboring quaternary referral academic center in the same healthcare system. Journal of Surgical Oncology. 119(1). 64–70. 10 indexed citations

Shaib, Walid L., Natalyn Hawk, Richard J. Cassidy, et al.. (2016). A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). International Journal of Radiation Oncology*Biology*Physics. 96(2). 296–303. 45 indexed citations

Moreno, Courtney C., Pardeep Mittal, Patrick S. Sullivan, et al.. (2015). Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation. Clinical Colorectal Cancer. 15(1). 67–73. 89 indexed citations

10.

Squires, Malcolm H., Volkan Adsay, David M. Schuster, et al.. (2015). Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Annals of Surgical Oncology. 22(7). 2295–2301. 78 indexed citations

11.

Hawk, Natalyn, Sungjin Kim, Zhengjia Chen, et al.. (2014). Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. American Journal of Clinical Oncology. 38(6). 543–549. 21 indexed citations

12.

Mahaseth, Hemchandra, Edith Brutcher, John Kauh, et al.. (2013). Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. Pancreas. 42(8). 1311–1315. 159 indexed citations

13.

Marcus, David M., et al.. (2013). Small cell carcinoma of the anus in the setting of prior squamous dysplasia and carcinoma in situ.. PubMed. 4(2). E1–4. 4 indexed citations

14.

Mahaseth, Hemchandra, John Kauh, Edith Brutcher, et al.. (2012). Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience.. Journal of Clinical Oncology. 30(15_suppl). e14614–e14614. 7 indexed citations

15.

Owonikoko, Taofeek K., R. Donald Harvey, John Kauh, et al.. (2012). A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.. Journal of Clinical Oncology. 30(15_suppl). 2576–2576. 3 indexed citations

16.

O’Regan, Ruth & Natalyn Hawk. (2011). mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opinion on Therapeutic Targets. 15(7). 859–872. 29 indexed citations

17.

Hawk, Natalyn, et al.. (2010). Metastatic sarcoma to the brain: Case series and literature review.. Journal of Clinical Oncology. 28(15_suppl). e20505–e20505. 1 indexed citations

18.

Wang, Xuerong, Natalyn Hawk, Ping Yue, et al.. (2008). Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biology & Therapy. 7(12). 1952–1958. 73 indexed citations

19.

Wang, Yan, Jiaxin Liu, Yun Wu, et al.. (2001). Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.. PubMed. 61(1). 138–44. 7 indexed citations

20.

Williams, Evan F., et al.. (1990). Changes in renal, platelet and cardiac nitrobenzylthioinosine binding in spontaneously hypertensive rats. Life Sciences. 46(14). 1007–1012. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact